연구성과로 돌아가기

2024 연구자 정보 (36 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Choi, Eun Jin
(Choi, EJ)
Daegu Catholic Univ, Med Ctr, Dept Pediat, Daegu, South Korea
Daegu Catholic Univ, Dept Pediat, Med Ctr, Daegu, South Korea


[JCR상위 1.5] Completion of the First Phase of Registration: Baseline Characteristics and Epidemiology of Hemophilia in Korea from the Korean Bleeding Disorder Registry (KBDR)
[JCR상위 33.2] The characteristics and treatment patterns in haemophilia B patients receiving recombinant coagulation factor IX
SCIE 1.5 HEMATOLOGY
Choi, Eun-Ji
(Choi, EJ)
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea

[JCR상위 1.5] Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b SCIE 1.5 HEMATOLOGY
Choi, Yunsuk
(Choi, Y)
Univ Ulsan, Coll Med, Asan Med Ctr, Coll Med, Seoul 138736, South Korea

[JCR상위 1.5] Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
[JCR상위 1.5] Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Alfa-2b: From a Phase 2 in South Korea
SCIE 1.5 HEMATOLOGY
Do, Young Rok
(Do, YR)
Keimyung Univ, Dongsan Med Ctr, Dept Hemato Oncol, Daegu, South Korea
Keimyung Univ, Dongsan Med Ctr, Dept Hematol, Sch Med, Daegu, South Korea
Dongsan Med Ctr, Dept Med, Daegu, South Korea
Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea
Keimyung Univ Dongsan Med Ctr, Dept Hematooncol, Daegu, South Korea
Keimyung Univ, Dongsan Med Ctr, Div Hematooncol, Daegu, South Korea
Keimyung Univ, Dongsan Med Ctr, Dept Hematooncol, Daegu 700712, South Korea


[JCR상위 1.5] Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service
[JCR상위 37.6] Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era
[JCR상위 24.0] Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma
[JCR상위 23.3] Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
[JCR상위 4.6] Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
[JCR상위 1.5] Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment
[JCR상위 37.2] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
[JCR상위 10.7] Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
SCIE 1.5 HEMATOLOGY
ONCOLOGY
MEDICINE, GENERAL & INTERNAL
HEMATOLOGY;ONCOLOGY
drydh1685@hotmail.com;
wskimsmc@skku.edu;
dhyoon@amc.seoul.kr;
kshmoon@dau.ac.kr;kihyunkimk@gmail.com;
Eissa, Yomna
(Eissa, Y)
제1저자 Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[JCR상위 1.5] The 66th ASH Annual Meeting Abstracts ORAL ABSTRACTS SCIE 1.5 HEMATOLOGY
Elemary, Mohamed
(Elemary, M)
Univ Saskatchewan, Prov Hematol & Blood & Marrow Transplant Program, Saskatchewan Canc Agcy, Saskatoon, SK, Canada
Univ Saskatchewan, Saskatchewan Canc Agcy, Prov Hematol & Blood & Marrow Transplant Program, Saskatoon, SK, Canada


[JCR상위 1.5] Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse
[JCR상위 1.5] The 66th ASH Annual Meeting Abstracts ORAL ABSTRACTS
[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?
SCIE 1.5 HEMATOLOGY
Garcia-Horton, Alejandro
(Garcia-Horton, A)
제1저자 McMaster Univ, Juravinski Hosp, Dept Oncol, Ancaster, ON, Canada
McMaster Univ, Canc Ctr, Dept Oncol, Ancaster, ON, Canada
AAE-4477-2021
Garcia-Horton, Alejandro

[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? SCIE 1.5 HEMATOLOGY
Ha, Jong-Won
(Ha, JW)
Yonsei Univ, Severance Hosp, Coll Med, Div Cardiol, Seoul, South Korea E-3893-2012
Ha, Jong
0000-0002-8260-2958
Ha, Jong-Won
[JCR상위 1.5] Effect of Evogliptin on the Progression of Aortic Valvular Calcification SCIE 1.5 CARDIAC & CARDIOVASCULAR SYSTEMS jksong@amc.seoul.kr;
Han, Sangwon
(Han, S)
Asan Med Ctr, Dept Nucl Med, Seoul, South Korea

[JCR상위 1.5] Effect of Evogliptin on the Progression of Aortic Valvular Calcification SCIE 1.5 CARDIAC & CARDIOVASCULAR SYSTEMS jksong@amc.seoul.kr;
Huang, He
(Huang, H)
Zhejiang Univ, Afliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? SCIE 1.5 HEMATOLOGY
Huang, Xiao Jun
(Huang, XJ)
Peking Univ, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplantat, Natl Clin Res Ctr Hematol Dis,Inst Hematol, Beijing, Peoples R China

[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? SCIE 1.5 HEMATOLOGY
Jamani, Kareem
(Jamani, K)
Univ Calgary, Tom Baker Canc Ctr, Cumming Sch Med, Calgary, AB, Canada

[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? SCIE 1.5 HEMATOLOGY
Jang, Youngeun
(Jang, Y)
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea
Kyungpook Natl Univ Hosp, Kyungpook Natl Univ, Sch Med, Dept Hematol Oncol, Daegu, South Korea


[JCR상위 1.5] Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service
[JCR상위 55.6] Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?
[JCR상위 9.5] Clinical effect of prophylactic pegfilgrastim in patients with newly diagnosed acute lymphoblastic leukemia who receive intensive chemotherapy
SCIE 1.5 HEMATOLOGY
HEALTH CARE SCIENCES & SERVICES;ONCOLOGY;REHABILITATION
baekdw83@gmail.com;
Jung, Jong Heon
(Jung, JH)
Natl Canc Ctr, Goyang, South Korea

[JCR상위 1.5] Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment SCIE 1.5 HEMATOLOGY
Kim, Dennis Dong Hwan
(Kim, DDH)
Princess Margaret Hosp, Hans Messner Allogene Transplant Program, Div Med Oncol & Hematol, Toronto, ON, Canada
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
AAH-8499-2019
Kim, Dennis

[JCR상위 1.5] Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse
[JCR상위 1.5] The 66th ASH Annual Meeting Abstracts ORAL ABSTRACTS
[JCR상위 18.1] Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
[JCR상위 1.5] Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?
SCIE 1.5 HEMATOLOGY
MULTIDISCIPLINARY SCIENCES
f0115@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
페이지 이동: